MYGN vs. FOLD, LGND, DVAX, BCRX, MNKD, CLDX, NVAX, OPK, GERN, and INVA
Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.
Myriad Genetics vs.
Amicus Therapeutics (NASDAQ:FOLD) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.
In the previous week, Myriad Genetics had 1 more articles in the media than Amicus Therapeutics. MarketBeat recorded 8 mentions for Myriad Genetics and 7 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.06 beat Myriad Genetics' score of 0.99 indicating that Amicus Therapeutics is being referred to more favorably in the media.
99.0% of Myriad Genetics shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Amicus Therapeutics received 57 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 72.98% of users gave Amicus Therapeutics an outperform vote while only 52.84% of users gave Myriad Genetics an outperform vote.
Amicus Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
Amicus Therapeutics presently has a consensus target price of $16.75, indicating a potential upside of 94.99%. Myriad Genetics has a consensus target price of $21.89, indicating a potential upside of 137.45%. Given Myriad Genetics' higher possible upside, analysts plainly believe Myriad Genetics is more favorable than Amicus Therapeutics.
Amicus Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500.
Amicus Therapeutics has a net margin of -10.62% compared to Myriad Genetics' net margin of -14.09%. Amicus Therapeutics' return on equity of 12.44% beat Myriad Genetics' return on equity.
Summary
Amicus Therapeutics beats Myriad Genetics on 12 of the 18 factors compared between the two stocks.
Get Myriad Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Myriad Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:MYGN) was last updated on 3/28/2025 by MarketBeat.com Staff
